AtriCure (ATRC) Reports In-Line Q3 EPS; Guides FY15 Revenue Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
AtriCure Reports Third Quarter 2015 Financial Results
October 27, 2015 4:01 PM EDTRevenue of $31.4 million up 17.8% as reported, 20.6% constant currency U.S. sales of $24.7 million up 23.0% International sales of $6.7 million up 2.1% as reported, 13.2% constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced third quarter 2015 financial results.
We are pleased with our performance in the third quarter and excited about our prospects for sustained growth, said Mike Carrel, President and Chief Executive... More
